Uticaj fosfolipaze C u norepinefrinom izazvan hipertrofični odgovor kardiomiocita
Phospholipase C in Cardiac Hypertrophy
Sažetak
Norepinephrine (NE) is known to mediate cardiomyocyte hypertrophy through the G protein coupled α1
-adrenoceptor (α1-AR) and the activation of the phosphoinositide-specific phospholipase C (PLC). Since the by-products of PLC activity are important downstream signal transducers for cardiac hypertrophy, the role
of and the regulatory mechanisms involved in the activation of PLC isozymes in cardiac hypertrophy are highlighted in this review. The discussion is focused to underscore PLC in different experimental models of cardiac hypertrophy, as well as in isolated adult and neonatal cardiomyocytes treated with NE. Particular
emphasis is laid concerning the α1-AR-PLC-mediated hypertrophic signalling pathway. From the information provided, it is evident that the specific activation of PLC isozymes is a primary signalling event in the α1
-AR mediated response to NE as well as initiation and progression of cardiac hypertrophy. Furthermore,
the possibility of PLC involvement in the perpetuation of cardiac hypertrophy is also described. It is suggested that specific PLC isozymes may serve as viable targets for the prevention of cardiac hypertrophy in patient population at-risk for the development of heart failure.
Reference
Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Med J 2020;5:15. doi: 10.21037/amj.2020.03.03.
World Health Organization. Cardiovascular diseases. Internet. Available at: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1. [Cited: 9-Feb-2022].
Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol 2016;13(6):368-78.
Dhalla NS, Saini-Chohan HK, Rodriguez-Leyva D, Elimban V, Dent MR, Tappia PS. Subcellular remodelling may induce cardiac dysfunction in congestive heart failure. Cardiovasc Res 2009;81(3):429-38.
Oldfield CJ, Duhamel TA, Dhalla NS. Mechanisms for the transition from physiological to pathological cardiac hypertrophy. Can J Physiol Pharmacol 2020;98(2):74-84.
Machackova J, Barta J, Dhalla NS. Myofibrillar remodeling in cardiac hypertrophy, heart failure and cardiomyopathies. Can J Cardiol 2006;22(11):953-68.
Dhalla NS, Dent MR, Tappia PS, Sethi R, Barta J, Goyal RK. Subcellular remodeling as a viable target for the treatment of congestive heart failure. J Cardiovasc Pharmacol Ther 2006;11(1):31-45.
Dhalla NS, Golfman L, Liu X, Sasaki H, Elimban V, Rupp H. Subcellular remodeling and heart dysfunction in cardiac hypertrophy due to pressure overload. Ann N Y Acad Sci 1999;874:100-10.
Shah AK, Bhullar SK, Elimban V, Dhalla NS. Oxidative stress as a mechanism for functional alterations in cardiac hypertrophy and heart failure. Antioxidants (Basel) 2021 Jun 8;10(6):931. doi: 10.3390/antiox10060931.
Tappia PS, Singal T. Phospholipid-mediated signalling and heart disease. Subcell Biochem 2008;49:299-324.
Tappia PS, Dent MR, Dhalla NS. Oxidative stress and redox regulation of phospholipase D in myocardial disease. Free Radic Biol Med 2006;41(3):349-61.
Dhalla NS, Xu YJ, Sheu SS, Tappia PS, Panagia V. Phosphatidic acid: a potential signal transducer for cardiac hypertrophy. J Mol Cell Cardiol 1997;29(11):2865-71.
Vines CM. Phospholipase C. Adv Exp Med Biol 2012;740:235-54.
Katan M, Cockcroft S. Phospholipase C families: Common themes and versatility in physiology and pathology. Prog Lipid Res 2020 Nov;80:101065. doi: 10.1016/j.plipres.2020.101065.
Suh PG, Ryu SH, Moon KH, Suh HW, Rhee SG. Cloning and sequence of multiple forms of phospholipase C. Cell 1988;54(2):161-9.
Harden TK, Sondek J. Regulation of phospholipase C isozymes by ras superfamily GTPases. Annu Rev Pharmacol Toxicol 2006;46:355-79.
Gresset A, Sondek J, Harden TK. The phospholipase C isozymes and their regulation. Subcell Biochem 2012;58:61-94.
Fukami K, Inanobe S, Kanemaru K, Nakamura Y. Phospholipase C is a key enzyme regulating intracellular calcium and modulating the phosphoinositide balance. Prog Lipid Res 2010;49(4):429-37.
Singh RM, Cummings E, Pantos C, Singh J. Protein kinase C and cardiac dysfunction: a review. Heart Fail Rev 2017;22(6):843-59.
He H, Wang W, Zhang H, Ma L, Wu H, Wang P, et al. Fosinopril and carvedilol reverse hypertrophy and change the levels of protein kinase C ε and components of its signalling complex. Cardiovasc Drugs Ther 2006;20(4):259-71.
Zeng C, Liang B, Jiang R, Shi Y, Du Y. Protein kinase C isozyme expression in right ventricular hypertrophy induced by pulmonary hypertension in chronically hypoxic rats. Mol Med Rep 2017;16(4):3833-40.
Ferreira JC, Brum PC, Mochly-Rosen D. βIIPKC and εPKC isozymes as potential pharmacological targets in cardiac hypertrophy and heart failure. J Mol Cell Cardiol 2011;51(4):479-84.
Nakamura Y, Fukami K. Regulation and physiological functions of mammalian phospholipase C. J Biochem 2017;161(4):315-21.
Yang YR, Follo MY, Cocco L, Suh PG. The physiological roles of primary phospholipase C. Adv Biol Regul 2013;53(3):232-41.
Tappia PS, Liu SY, Shatadal S, Takeda N, Dhalla NS, Panagia V. Changes in sarcolemmal PLC isoenzymes in postinfarct congestive heart failure: partial correction by imidapril. Am J Physiol 1999;277(1):H40-9.
Suh P-G, Ryu SO, Choi WC, Lee KY, Rhee S. G.Monoclonal antibodies to three phospholipase C isozymes from bovine brain. J Biol Chem 1988;263:14497-504.
Hansen CA, Schroering AG, Robishaw JD. Subunit expression of signal transducing G proteins in cardiac tissue: implications for phospholipase C-beta regulation. J Mol Cell Cardiol 1995;27(1):471-84.
Schnabel P, Gäs H, Nohr T, Camps M, Böhm M. Identification and characterization of G protein-regulated phospholipase C in human myocardium. J Mol Cell Cardiol 1996;28(12):2419-27.
Wolf R. A. Specific expression of phospholipase C-δ1 and γ1 by adult cardiac ventricular myocytes (Abstract). Circulation 1993; 88, Suppl 1:I-241.
Smrcka AV, Brown JH, Holz GG. Role of phospholipase Cε in physiological phosphoinositide signalling networks. Cell Signal 2012;24(6):1333-43.
Otaegui D, Querejeta R, Arrieta A, Lazkano A, Bidaurrazaga A, Arriandiaga JR, et al. Phospholipase Cβ4 isozyme is expressed in human, rat, and murine heart left ventricles and in HL-1 cardiomyocytes. Mol Cell Biochem 2010;337(1-2):167-73.
Rhee SG. Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem 2001;70:281-312.
Lee CW, Lee KH, Lee SB, Park D, Rhee SG. Regulation of phospholipase C-β4 by ribonucleotides and the alpha subunit of Gq. J Biol Chem 1994;269(41):25335-8.
Fisher IJ, Jenkins ML, Tall GG, Burke JE, Smrcka AV. Activation of phospholipase C β by Gβγ and Gαq involves C-terminal rearrangement to release autoinhibition. Structure 2020;28(7):810-9.
Madukwe JC, Garland-Kuntz EE, Lyon AM, Smrcka AV. G protein βγ subunits directly interact with and activate phospholipase Cϵ. J Biol Chem 2018;293(17):6387-97.
Cockcroft S, Thomas GM. Inositol-lipid-specific phospholipase C isoenzymes and their differential regulation by receptors. Biochem J 1992;288( Pt 1):1-14.
Sekiya F, Bae YS, Rhee SG. Regulation of phospholipase C isozymes: activation of phospholipase C-gamma in the absence of tyrosine-phosphorylation. Chem Phys Lipids 1999;98(1-2):3-11.
Tappia PS, Padua RR, Panagia V, Kardami E. Fibroblast growth factor-2 stimulates phospholipase Cbeta in adult cardiomyocytes. Biochem Cell Biol 1999;77(6):569-75.
Tall E, Dormán G, Garcia P, Runnels L, Shah S, Chen J, et al. Phosphoinositide binding specificity among phospholipase C isozymes as determined by photo-cross-linking to novel substrate and product analogs. Biochemistry 1997;36(23):7239-48.
Yagisawa H, Sakuma K, Paterson HF, Cheung R, Allen V, Hirata H, et al. Replacements of single basic amino acids in the pleckstrin homology domain of phospholipase C-δ1 alter the ligand binding, phospholipase activity, and interaction with the plasma membrane. J Biol Chem 1998;273(1):417-24.
Im MJ, Gray C, Rim AJ. Characterization of a phospholipase C activity regulated by the purified Gh in reconstitution systems. J Biol Chem 1992;267(13):8887-94.
Dupuis M, Houdeau E, Mhaouty-Kodja S. Increased potency of α1-adrenergic receptors to induce inositol phosphates production correlates with the up-regulation of α1d/Gh α/phospholipase C δ1 signalling pathway in term rat myometrium. Reproduction 2008;135(1):55-62.
Lin YF, Yeh TS, Chen SF, Tsai YH, Chou CM, Yang YY, et al. Nonmuscle myosin IIA (myosin heavy polypeptide 9): a novel class of signal transducer mediating the activation of Gαh/phospholipase C-δ1 pathway. Endocrinology 2010;151(3):876-85.
Grubb DR, Iliades P, Cooley N, Yu YL, Luo J, Filtz TM, et al. Phospholipase Cβ1b associates with a Shank3 complex at the cardiac sarcolemma. FASEB J 2011;25(3):1040-7.
Kawaguchi H, Sano H, Iizuka K, Okada H, Kudo T, Kageyama K, et al. Phosphatidylinositol metabolism in hypertrophic rat heart. Circ Res 1993;72(5):966-72.
Shoki M, Kawaguchi H, Okamoto H, Sano H, Sawa H, Kudo T, et al. Phosphatidylinositol and inositolphosphatide metabolism in hypertrophied rat heart. Jpn Circ J 1992;56(2):142-7.
Schnabel P, Mies F, Nohr T, Geisler M, Böhm M. Differential regulation of phospholipase C-beta isozymes in cardiomyocyte hypertrophy. Biochem Biophys Res Commun 2000;275(1):1-6.
Arthur JF, Matkovich SJ, Mitchell CJ, Biden TJ, Woodcock EA. Evidence for selective coupling of α1-adrenergic receptors to phospholipase C-β1 in rat neonatal cardiomyocytes. J Biol Chem 2001;276(40):37341-6.
D'Angelo DD, Sakata Y, Lorenz JN, Boivin GP, Walsh RA, Liggett SB, et al. Transgenic Gαq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci 1997;94 (15):8121-6.
Sakata Y, Hoit BD, Liggett SB, Walsh RA, Dorn GW 2nd. Decompensation of pressure-overload hypertrophy in Gαq-overexpressing mice. Circulation 1998;97(15):1488-95.
Adams JW, Sakata Y, Davis MG, Sah VP, Wang Y, Liggett SB, et al. Enhanced Gαq signalling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci 1998;95(17):10140-5.
Sussman MA, Welch S, Walker A, Klevitsky R, Hewett TE, Price RL, et al. Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1. J Clin Invest 2000;105(7):875-86.
Mende U, Semsarian C, Martins DC, Kagen A, Duffy C, Schoen FJ, et al. Dilated cardiomyopathy in two transgenic mouse lines expressing activated G protein αq: lack of correlation between phospholipase C activation and the phenotype. J Mol Cell Cardiol 2001;33(8):1477-91.
Mende U, Kagen A, Cohen A, Aramburu J, Schoen FJ, Neer EJ. Transient cardiac expression of constitutively active Gαq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl Acad Sci 1998;95(23):13893-8.
Wu J, Zhang C, Liu C, Zhang A, Li A, Zhang J, et al. Aortic constriction induces hypertension and cardiac hypertrophy via (pro)renin receptor activation and the PLC‑β3 signalling pathway. Mol Med Rep 2019; 19 (1):573-80.
Zhang L, Malik S, Kelley GG, Kapiloff MS, Smrcka AV. Phospholipase C ε scaffolds to muscle-specific A kinase anchoring protein (mAKAPβ) and integrates multiple hypertrophic stimuli in cardiac myocytes. J Biol Chem 2011;286(26):23012-21.
Wang H, Oestreich EA, Maekawa N, Bullard TA, Vikstrom KL, Dirksen RT, et al. Phospholipase C ε modulates β-adrenergic receptor-dependent cardiac contraction and inhibits cardiac hypertrophy. Circ Res 2005;97(12):1305-13.
Dent MR, Dhalla NS, Tappia PS. Phospholipase C gene expression, protein content and activities in cardiac hypertrophy and heart failure due to volume overload. Am J Physiol 2004;282:H719-27.
Dent MR, Aroutiounova N, Dhalla NS, Tappia PS. Losartan attenuates phospholipase C isozyme gene expression in hypertrophied hearts due to volume overload. J Cell Mol Med 2006;10:470-9.
Jalili T, Takeishi Y, Song G, Ball NA, Howles G, Walsh RA. PKC translocation without changes in Gαq and PLC-β protein abundance in cardiac hypertrophy and failure. Am J Physiol 1999;277(6):H2298-304.
Ruwhof C, van Wamel JT, Noordzij LA, Aydin S, Harper JC, van der Laarse A. Mechanical stress stimulates phospholipase C activity and intracellular calcium ion levels in neonatal rat cardiomyocytes. Cell Calcium 2001;29(2):73-83.
Ganguly PK, Lee SL, Beamish RE, Dhalla NS. Altered sympathetic system and adrenoceptors during the development of cardiac hypertrophy. Am Heart J 1989;118 (3):520-5.
Das M, Das DK. Caveolae, caveolin, and cavins: potential targets for the treatment of cardiac disease. Ann Med 2012;44(6):530-41.
Gazzerro E, Sotgia F, Bruno C, Lisanti MP, Minetti C. Caveolinopathies: from the biology of caveolin-3 to human diseases. Eur J Hum Genet 2010;18(2):137-45.
Fujita T, Toya Y, Iwatsubo K, Onda T, Kimura K, Umemura S, et al. Accumulation of molecules involved in alpha1-adrenergic signal within caveolae: caveolin expression and the development of cardiac hypertrophy. Cardiovasc Res 2001;51(4):709-16.
Grubb DR, Vasilevski O, Huynh H, Woodcock EA. The extreme C-terminal region of phospholipase Cbeta1 determines subcellular localization and function; the "b" splice variant mediates alpha1-adrenergic receptor responses in cardiomyocytes. FASEB J 2008;22(8):2768-74.
Filtz TM, Grubb DR, McLeod-Dryden TJ, Luo J, Woodcock EA. Gq-initiated cardiomyocyte hypertrophy is mediated by phospholipase Cβ1b. FASEB J 2009;23(10):3564-70.
Singal T, Dhalla NS, Tappia PS. Phospholipase C may be involved in norepinephrine-induced cardiac hypertrophy. Biochem Biophys Res Commun 2004;320(3):1015-9.
Singal T, Dhalla NS, Tappia PS. Regulation of c-Fos and c-Jun gene expression by phospholipase C activity in adult cardiomyocytes. Mol Cell Biochem 2009;327(1-2):229-39.
Singal T, Dhalla NS, Tappia PS. Reciprocal regulation of transcription factors and PLC isozyme gene expression in adult cardiomyocytes. J Cell Mol Med 2010;14(6B):1824-35.
Small K, Feng JF, Lorenz J, Donnelly ET, Yu A, Im MJ, et al. Cardiac specific overexpression of transglutaminase II (Gh) results in a unique hypertrophy phenotype independent of phospholipase C activation. J Biol Chem 1999;274(30):21291-6.
Giles TD, Sander GE, Thomas MG, Quiroz AC. α-adrenergic mechanisms in the pathophysiology of left ventricular heart failure-An analysis of their role in systolic and diastolic dysfunction. J Mol Cell Cardiol 1996;18:33-43.
Prasad K, O’Neil CL, Bharadwaj B. Effect of prolonged prazosin treatment on hemodynamic and biochemical changes in the dog heart due to chronic pressure overload. Jpn Heart J 1984;25:461-76.
Strauer BE. Progression and regression of heart hypertrophy in arterial hypertension: pathophysiology and clinical aspects. Z Kardiol 1995;74:171-8.
Strauer BE. Regression of myocardial and coronary vascular hypertrophy in hypertensive heart disease. J Cardiovasc Pharmacol 1988;12:S45-54.
Strauer BE, Bayer F, Brecht HM, Motz W. The influence of sympathetic nervous activity on regression of cardiac hypertrophy. J Hypertens Suppl 1985;3(4):S39-44.
Motz W, Klepzig M, Strauer BE. Regression of cardiac hypertrophy: experimental and clinical results. J Cardiovasc Pharmacol 1987;10 Suppl 6:S148-52.
Barac YD, Zeevi-Levin N, Yaniv G, Reiter I, Milman F, Shilkrut M, et al. The 1,4,5-inositol trisphosphate pathway is a key component in Fas-mediated hypertrophy in neonatal rat ventricular myocytes. Cardiovasc Res 2005;68(1):75-86.
Kockskämper J, Zima AV, Roderick HL, Pieske B, Blatter LA, Bootman MD. Emerging roles of inositol 1,4,5-trisphosphate signalling in cardiac myocytes. J Mol Cell Cardiol 2008;45(2):128-47.
de Rubio RG, Ransom RF, Malik S, Yule DI, Anantharam A, Smrcka AV. Phosphatidylinositol 4-phosphate is a major source of GPCR-stimulated phosphoinositide production. Sci Signal 2018 Sep 11;11(547):eaan1210. doi: 10.1126/scisignal.aan1210.
Malik S, deRubio RG, Trembley M, Irannejad R, Wedegaertner PB, Smrcka AV. G protein βγ subunits regulate cardiomyocyte hypertrophy through a perinuclear Golgi phosphatidylinositol 4-phosphate hydrolysis pathway. Mol Biol Cell 2015;26(6):1188-98.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).